Cullinan Therapeutics, Inc. - 8-K Filing
Zipalertinib plus chemotherapy showed statistically significant improvement in progression-free survival (PFS) for first-line treatment of EGFR exon 20 insertion mutation NSCLC patients. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CGEM